Páramo-Rivas F, Tovar-Serrano A, Rendón-Macías ME

Language: Spanish
References: 12
Page: 34-40
PDF size: 460.49 Kb.

ABSTRACT

Background: Urinary tract infection (UTI) is the third leading cause of morbidity from infections, diagnosis and appropriate treatment involves the determination of the pathogen and antimicrobial sensitivity or resistance. The empirical treatment of patients with extended spectrum beta lactamase (ESBL) bacteria lead the progression of the disease by an ineffective treatment.
Objective: To identify the frequency of pathogens and antimicrobial resistance patterns of microorganisms isolated from patients with community-acquired urinary tract infection, hospitalized at Internal Medicine Service of Nuevo Sanatorio Durango, Mexico City.
Material and method: A prospective, observational, single-center cross-sectional descriptive study was conducted. They were selected hospitalized patients with UTI in the internal medicine service of Nuevo Sanatorio Durango, Mexico City. Microorganisms were isolated from the urine of patients by culture, strains were typed by biochemical tests and susceptibility testing and resistance were performed.
Results: In patients with urinary symptoms (n=78) urine culture was performed and in 46, bacterial isolates were obtained. Escherichia coli was identified in 91.5% and within this group 38.3% showed positive ESBL features. The greatest resistance was against ampicillin-sulbactam, ciprofloxacin, ceftriaxone and TMP/SMZ.
Conclusions: This study demonstrated the high incidence of beta-lactamase- producing organisms in UTI patients hospitalized in the internal medicine at New Hospital in Durango, Mexico. This study will improve clinical guide empirical therapy in patients with urinary tract infections.

REFERENCES

1. Principales casos nuevos de enfermedades. Inegi 2010. www.inegi.org.

2. Guía de práctica clínica, diagnóstico y tratamiento de la infección aguda, no complicada del tracto urinario en la mujer. México: Secretaría de Salud, 2009.

3. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003;49:71-82.

4. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:103-120.

5. Arredondo-Garcia JL, Soriano-Becerril D, Solorzano- Santos F, Arbo-Sosa A, et al. Resistance of uropathogenic bacteria to first-line antibiotics in Mexico City: A multicenter susceptibility analysis. Curr Ther Res Clin Exp 2007;68:120-126.

6. Gniadkowski M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infec 2001;7:597-608.

7. Chaudhary U, Aggarwal R. Extended spectrum-lactamases (ESBL) -an emerging threat to clinical therapeutics Indian J Med Microbiol 2004;22:75-80.

8. Valdevenito S JP. Infección urinaria recurrente en la mujer. Rev Chilena Infectol 2008;25:268-276.

9. Valdivieso RF, Trucco AO, Prado JV, Díaz J MC, Ojeda SA. Resistencia a los antimicrobianos en agentes causantes de infección del tracto urinario en 11 hospitales chilenos. Proyecto PRONARES. Rev Med Chile 1999;127:1033- 1040.

10. Villafañe Ferrer LM. Etiología y perfil de resistencia a antimicrobianos de uropatógenos aislados en dos hospitales de Cartagena. Ciencia Salud Virtual 2013;5:18-25.

11. Caicedo SP, Martínez T, Meneses E, et al. Etiología y resistencia bacteriana en infección de vias urinarias en el Hospital Universitario San José de Popayán, Colombia, entre enero y diciembre de 2008. Rev Urol Col 2009;18:13.

12. Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008;32:534-537.